LB Pharmaceuticals (LBRX.US) is sprinting towards Nasdaq and is planning to raise $100 million, potentially breaking through the biotech IPO winter.

According to the Securities Times APP, focusing on biotechnology company LB Pharmaceuticals, which specializes in drugs for neurological and mental illnesses, submitted an application for an initial public offering (IPO) in the US stock market last Friday, with a scale of about $100 million. This marks the first significant new IPO application from an innovative drug developer or biotechnology company since January of this year.